According to a recent LinkedIn post from Neuromod Devices Ltd, company representatives are present at the CEORL-HNS 2026 conference in Gothenburg, Sweden, alongside clinical partners using its Lenire tinnitus treatment device. The post highlights discussions with providers from HØR and Audioteket Sverige AB focused on real-world clinical outcomes for tinnitus patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Neuromod is actively engaging with ear, nose and throat and audiology specialists, which may support broader clinical adoption and reimbursement discussions for Lenire. Increased visibility at a major European conference could help strengthen the company’s positioning in the tinnitus and hearing health market, potentially supporting future revenue growth if clinical uptake continues to expand.